Literature DB >> 23082866

Gene doping: gene delivery for olympic victory.

David Gould1.   

Abstract

With one recently recommended gene therapy in Europe and a number of other gene therapy treatments now proving effective in clinical trials it is feasible that the same technologies will soon be adopted in the world of sport by unscrupulous athletes and their trainers in so called 'gene doping'. In this article an overview of the successful gene therapy clinical trials is provided and the potential targets for gene doping are highlighted. Depending on whether a doping gene product is secreted from the engineered cells or is retained locally to, or inside engineered cells will, to some extent, determine the likelihood of detection. It is clear that effective gene delivery technologies now exist and it is important that detection and prevention plans are in place.
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Keywords:  detection; gene doping; gene therapy; secreted proteins; sport; transcription factors

Mesh:

Year:  2013        PMID: 23082866      PMCID: PMC3731603          DOI: 10.1111/bcp.12010

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  35 in total

1.  Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.

Authors:  Janaiah Kota; Chalonda R Handy; Amanda M Haidet; Chrystal L Montgomery; Amy Eagle; Louise R Rodino-Klapac; Danielle Tucker; Christopher J Shilling; Walter R Therlfall; Christopher M Walker; Steven E Weisbrode; Paul M L Janssen; K Reed Clark; Zarife Sahenk; Jerry R Mendell; Brian K Kaspar
Journal:  Sci Transl Med       Date:  2009-11-11       Impact factor: 17.956

2.  AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

Authors:  Peter A LeWitt; Ali R Rezai; Maureen A Leehey; Steven G Ojemann; Alice W Flaherty; Emad N Eskandar; Sandra K Kostyk; Karen Thomas; Atom Sarkar; Mustafa S Siddiqui; Stephen B Tatter; Jason M Schwalb; Kathleen L Poston; Jaimie M Henderson; Roger M Kurlan; Irene H Richard; Lori Van Meter; Christine V Sapan; Matthew J During; Michael G Kaplitt; Andrew Feigin
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

3.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

4.  Gene therapy for pain: results of a phase I clinical trial.

Authors:  David J Fink; James Wechuck; Marina Mata; Joseph C Glorioso; James Goss; David Krisky; Darren Wolfe
Journal:  Ann Neurol       Date:  2011-07-27       Impact factor: 10.422

5.  PGC-1alpha regulates a HIF2alpha-dependent switch in skeletal muscle fiber types.

Authors:  Kyle A Rasbach; Rana K Gupta; Jorge L Ruas; Jun Wu; Elnaz Naseri; Jennifer L Estall; Bruce M Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-24       Impact factor: 11.205

6.  Safety and efficacy of gene transfer for Leber's congenital amaurosis.

Authors:  Albert M Maguire; Francesca Simonelli; Eric A Pierce; Edward N Pugh; Federico Mingozzi; Jeannette Bennicelli; Sandro Banfi; Kathleen A Marshall; Francesco Testa; Enrico M Surace; Settimio Rossi; Arkady Lyubarsky; Valder R Arruda; Barbara Konkle; Edwin Stone; Junwei Sun; Jonathan Jacobs; Lou Dell'Osso; Richard Hertle; Jian-xing Ma; T Michael Redmond; Xiaosong Zhu; Bernd Hauck; Olga Zelenaia; Kenneth S Shindler; Maureen G Maguire; J Fraser Wright; Nicholas J Volpe; Jennifer Wellman McDonnell; Alberto Auricchio; Katherine A High; Jean Bennett
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

7.  Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass.

Authors:  N Kinouchi; Y Ohsawa; N Ishimaru; H Ohuchi; Y Sunada; Y Hayashi; Y Tanimoto; K Moriyama; S Noji
Journal:  Gene Ther       Date:  2008-03-06       Impact factor: 5.250

8.  A novel hybrid promoter responsive to pathophysiological and pharmacological regulation.

Authors:  Maria C Subang; Rewas Fatah; Carly Bright; Patricia Blanco; Mariana Berenstein; Ying Wu; Osvaldo L Podhajcer; Paul G Winyard; Yuti Chernajovsky; David Gould
Journal:  J Mol Med (Berl)       Date:  2011-10-30       Impact factor: 4.599

9.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Authors:  Amit C Nathwani; Edward G D Tuddenham; Savita Rangarajan; Cecilia Rosales; Jenny McIntosh; David C Linch; Pratima Chowdary; Anne Riddell; Arnulfo Jaquilmac Pie; Chris Harrington; James O'Beirne; Keith Smith; John Pasi; Bertil Glader; Pradip Rustagi; Catherine Y C Ng; Mark A Kay; Junfang Zhou; Yunyu Spence; Christopher L Morton; James Allay; John Coleman; Susan Sleep; John M Cunningham; Deokumar Srivastava; Etiena Basner-Tschakarjan; Federico Mingozzi; Katherine A High; John T Gray; Ulrike M Reiss; Arthur W Nienhuis; Andrew M Davidoff
Journal:  N Engl J Med       Date:  2011-12-10       Impact factor: 176.079

10.  A sequence polymorphism in MSTN predicts sprinting ability and racing stamina in thoroughbred horses.

Authors:  Emmeline W Hill; Jingjing Gu; Suzanne S Eivers; Rita G Fonseca; Beatrice A McGivney; Preethi Govindarajan; Nick Orr; Lisa M Katz; David E MacHugh; David MacHugh
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more
  2 in total

1.  Biological therapies: a long way on from Jenner.

Authors:  Albert Ferro; Malcolm Boyce
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

2.  Editors' pick 2013.

Authors:  Albert Ferro; Yoon K Loke; Lionel D Lewis; Andrew Somogyi; Adam F Cohen; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.